Gilman Hill Asset Management LLC boosted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 13.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,744 shares of the medical research company's stock after purchasing an additional 559 shares during the quarter. Gilman Hill Asset Management LLC's holdings in Thermo Fisher Scientific were worth $2,577,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Cadence Bank NA raised its holdings in shares of Thermo Fisher Scientific by 0.3% in the 1st quarter. Cadence Bank NA now owns 7,050 shares of the medical research company's stock worth $4,164,000 after buying an additional 18 shares in the last quarter. S. R. Schill & Associates lifted its holdings in Thermo Fisher Scientific by 5.5% during the fourth quarter. S. R. Schill & Associates now owns 385 shares of the medical research company's stock worth $257,000 after acquiring an additional 20 shares in the last quarter. Wiley BROS. Aintree Capital LLC raised its stake in shares of Thermo Fisher Scientific by 2.5% in the 1st quarter. Wiley BROS. Aintree Capital LLC now owns 833 shares of the medical research company's stock valued at $492,000 after purchasing an additional 20 shares during the period. Bridgewater Advisors Inc. raised its stake in shares of Thermo Fisher Scientific by 1.7% in the 1st quarter. Bridgewater Advisors Inc. now owns 1,229 shares of the medical research company's stock valued at $726,000 after purchasing an additional 20 shares during the period. Finally, Forefront Analytics LLC raised its stake in shares of Thermo Fisher Scientific by 3.9% in the 1st quarter. Forefront Analytics LLC now owns 528 shares of the medical research company's stock valued at $317,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 86.50% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on TMO. Barclays reduced their price target on Thermo Fisher Scientific from $685.00 to $595.00 and set an "overweight" rating for the company in a report on Monday, September 12th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an "overweight" rating in a research report on Friday, July 29th. Credit Suisse Group began coverage on shares of Thermo Fisher Scientific in a report on Wednesday, August 24th. They set a "neutral" rating and a $675.00 price target for the company. Finally, SVB Leerink increased their price objective on Thermo Fisher Scientific from $630.00 to $650.00 and gave the company an "outperform" rating in a report on Friday, July 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $656.56.

Insider Buying and Selling at Thermo Fisher Scientific

Thermo Fisher Scientific Trading Down 0.4 %

Shares of TMO traded down $2.05 during midday trading on Friday, hitting $518.24. The stock had a trading volume of 8,920 shares, compared to its average volume of 1,076,331. Thermo Fisher Scientific Inc. has a 1 year low of $497.83 and a 1 year high of $672.34. The firm has a market cap of $203.04 billion, a PE ratio of 27.69, a price-to-earnings-growth ratio of 1.64 and a beta of 0.85. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 1.13. The stock's 50 day moving average is $567.60 and its 200 day moving average is $558.21.

Thermo Fisher Scientific (NYSE:TMO – Get Rating) last posted its earnings results on Thursday, July 28th. The medical research company reported $5.51 EPS for the quarter, beating analysts' consensus estimates of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The business had revenue of $10.97 billion for the quarter, compared to the consensus estimate of $9.95 billion. During the same quarter last year, the firm posted $5.60 EPS. The company's revenue for the quarter was up 18.3% on a year-over-year basis. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Thursday, September 15th will be paid a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date of this dividend is Wednesday, September 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 6.39%.

Thermo Fisher Scientific Profile

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

• Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
• Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
• 2 Semiconductor Stocks To Watch For Reversals
• Will Crowdstrike Get A Boost From Increased EPS Guidance?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• What Steelcase's Earnings Say About the Return to the Office?

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.